Promising phase 1 trial results: Use of sotorasib (AMG 510) in patients with solid tumors

This study has, in some cases, demonstrated a median progression-free survival that is two times longer than what we encounter in patients today.'
Source: EurekAlert! - Biology - Category: Biology Source Type: news